Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy

Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a globally poor outcome, especially in patients ineligible for intensive chemotherapy. Until recently, therapeutic options for these patients included low-dose cytarabine (LDAC) or the hypomethylating agents (HMA) azacitidin...

Descripción completa

Detalles Bibliográficos
Autores principales: Richard-Carpentier, Guillaume, DiNardo, Courtney D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811760/
https://www.ncbi.nlm.nih.gov/pubmed/31692757
http://dx.doi.org/10.1177/2040620719882822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811760/
https://www.ncbi.nlm.nih.gov/pubmed/31692757
http://dx.doi.org/10.1177/2040620719882822

Ejemplares similares